Current Headlines

  1. Merck And Advaxis Partner In Prostate Immunotherapy Trial
    9/2/2014

    Clinical stage biotech firm Advaxis announced that it has partnered with Merck to conduct a clinical trial investigating its cancer immunotherapy ADXS-PSA with Merck's investigational anti PD-1 antibody pembrolizumab. The combination therapy will be evaluated in a Phase I/II study involving patients who have undergone treatment for metastatic, castration-resistant prostate cancer.

  2. EC Designates Innate’s CTCL Antibody As Orphan Drug
    9/2/2014

    Innate Pharma, a biopharmaceutical company developing innate immunity drug candidates, announced that the European Commission has awarded Orphan Medicinal Product Designation to its antibody IPH4102 for the treatment of cutaneous T-cell lymphoma (CTCL).

  3. New Animal Resource Facility India’s Latest R&D Move
    9/2/2014

    India’s department of health research announced that the country plans to build its first ever National Animal Resource facility for biomedical research that will only accept animals of a “defined quality.” This will empower researchers to obtain more reliable results for vaccine development.

  4. Researchers: Proteins That Promote HIV/Ebola Virus Also Inhibit Release
    8/28/2014

    In an unexpected discovery, scientists at Missouri University have found that proteins that promote the entry of viruses like HIV and Ebola into host cells also possess the ability to block the release of these diseases. Scientists feel this discovery helps to better the understanding of these viruses and could lead to new therapies for stopping their progression.

  5. AB SCIEX, Dalton To Develop New ADC Analysis Methods
    8/28/2014

    AB SCIEX and Dalton Pharma announced they will collaborate on the development of a new comprehensive method for analyzing Antibody-Drug Conjugates (ADC) with hopes of bringing more biological oncology therapies to market.

  6. C4XD Lends Its NMR Technology To Takeda For 3D Drug Molecule Structures
    8/28/2014

    C4X Discovery (C4XD) announced in a press release that it will lend its Nuclear Magnetic Resonance (NMR) technology to Takeda Cambridge Limited (TCB). The new partners seek to use the technology to make 3D identifications of TCB’s drug molecules. Piers Morgan, CEO of C4XD, said, "We are delighted to partner with TCB, a leading pharma company with world class target identification and validation capabilities. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD's technology."

  7. Antitope To Partner With UCL In Antibody Project
    8/27/2014

    Antitope, an Abzena firm focused on biopharmaceutical development, announced its collaboration with the University College London (UCL) to humanize an anti-LRG1 antibody in order to inhibit cancer growth and spread.

  8. Alexion Launches Eculizumab Trial In Kidney Transplant DGF
    8/27/2014

    Alexion announced that it has started dosing in its clinical trial evaluating eculizumab for the prevention of delayed graft function (DGF). The trial involves adult patients who have undergone kidney transplantation and who are at increased risk of DGF.

  9. Alkermes Submits NDA For New Schizophrenia Drug
    8/27/2014

    Alkermes yesterday announced its submission of a New Drug Application (NDA) to the U.S. FDA for its much awaited schizophrenia drug, aripiprazole lauroxil. The drug is a long-acting injectable atypical antipsychotic, which if approved, will be a novel once-monthly treatment for schizophrenia.

  10. DPx Holdings B.V. Reaches Definitive Agreement To Acquire Gallus BioPharmaceuticals
    8/27/2014

    DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners. Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.